How Fulgent Genetics Wowed With Its Q4 Results

Keith Speights, The Motley Fool
·3 min read
How Fulgent Genetics Wowed With Its Q4 Results

The genetic-testing company provided its fourth-quarter update after the market close on Thursday. In the prior-year period, Fulgent posted a GAAP net loss of $296 million, or $0.01 per share. COVID-19 is pretty much all you need to know about Fulgent's stellar fourth-quarter results.